Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:46 2024-05-02 am EDT			5-day change	1st Jan Change
48.6 ^PLN	-1.82%		-1.42%	-15.48%

Mar. 13	Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	CI

Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm

August 16, 2022

Ryvu Therapeutics S.A. announced that it has received €22 million in a round of funding from new investor, European Fund for Strategic Investments, a fund managed by European Investment Bank, Investment Arm on August 17, 2022.

Latest news about Ryvu Therapeutics S.A.

Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	Mar. 06	CI
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	Feb. 14	CI
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	Jan. 31	CI
Transcript : Ryvu Therapeutics S.A. - Special Call	Dec. 11
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	Dec. 07	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Transcript : Ryvu Therapeutics S.A. - Special Call	23-10-23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23-10-23	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-13	CI
Ryvu and TIM to enter Warsaw's mWIG40 index	23-08-31	RE
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	22-12-11	CI
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	22-11-30	MT
BioNTech to Make $21 Million Equity Investment in Ryvu Therapeutics	22-11-30	MT
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	22-11-30	CI
Ryvu Therapeutics S.A. announced that it expects to receive ?20 million in funding from BioNTech SE	22-11-29	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	22-11-03	CI
Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium	22-10-26	CI
Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.899998 million in funding	22-10-05	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-28	CI
Poland's Ryvu Therapeutics Bags $22 Million EU Financing To Develop New Cancer Drugs	22-08-17	MT
Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm	22-08-16	CI

Chart Ryvu Therapeutics S.A.

Duration

Period

More charts

Company Profile

Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Companyâs portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ryvu Therapeutics S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

48.6 PLN

Average target price

73.12 PLN

Spread / Average Target

+50.46%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RYVU THERAPEUTICS S.A.	-15.48%	280M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs